Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & Translation into Clinic
Welcome to the Inaugural Proteomics Based Drug Discovery Summit!
Accelerating Small Molecule Drugs from Discovery
to Clinic through Pioneering Proteomics
Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.
This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.
The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the “undruggable”.
In 2025, make sure you join experts where you will hear exclusive data revealed, towards supercharging your experiments for screening compound libraries, unravelling the mechanism of action, deconvoluting protein-protein interactions and determining drug potency to gear your proteomics platforms for faster development of more effective drugs to change patient lives.
Attending Companies Include:
Top Testimonials:
Rhushikesh Kulkarni
Principal Scientist
(Oncology Chemical Biology)
New York University
I am looking forward to learning about the recent advances in MS technologies, the innovative solutions that experts have devised to tackle industry challenges, and their application in
driving drug discovery.
Events like this provide an opportunity to present recent data, disseminate knowledge, and allow focused discussions on the ways to improve proteomics-based drug discovery platform to achieve
best results.
Jagat Adhikari
Associate Director
Proteomics Platform
I am looking forward to learning about the recent advances in MS technologies, the innovative solutions that experts have devised to tackle industry challenges, and their application in driving drug discovery.
Rhushikesh Kulkarni, Principal Scientist (Oncology Chemical Biology), New York University
Events like this provide an opportunity to present recent data, disseminate knowledge, and allow focused discussions on the ways to improve proteomics based drug discovery platform to achieve best results.
Jagat Adhikari, Associate Director, Proteomics Platform
Other Events in the Series:
